Salvage therapy with sorafenib–FLAG–Amsa, involving only 7 days of sorafenib exposure before chemotherapy, was an economically prudent, well-tolerated and efficacious regimen in relapsed/refractory FLT3-ITD AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.